United States Federal Circuit

ResetAA Font size: Print

Amgen Inc USA v. Sanofi LLC, 17-1480

Affirming the district court's grant of JMOL of non-obviousness in a patent case involving cholesterol drugs, but vacating the district court's permanent injunction and remanding for a new trial on written description and enablement, holding that the district court erred by excluding the appellant's evidence regarding written description and enablement and improperly instructed the jury on written description.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/10/05




  • United States Federal Circuit


FindLaw Career Center

    Select a Job Title

      Post a Job  |  Careers Home

    View More